OBJECTIVES We report our 8-year experience in transcatheter aortic and mitral valve-in-valve (VinV) implantation.
. In all subsequent cases, bovine Edwards SAPIEN and SAPIEN XT valves were implanted through either a transfemoral or transapical approach. Transapical access was the only approach that was used for mitral VinV implantation.
All operations were performed in our hybrid operating room equipped with standby cardiopulmonary bypass support. The techniques of transcatheter aortic and mitral VinV implantation were described previously (4, 14, 15) . Balloon valvuloplasty of the bioprosthesis was utilized in our initial experience, but was subsequently not utilized during transapical Ye et al. Figure 1A ). Peripheral vascular disease and previous stroke were independent risk factors for reduced midterm survival, with hazard ratios of 3.2 and 3.0, respectively ( Table 3) . Female patients appeared to have relatively poor survival ( Figure 1D ). There was no significant difference in late survival between patients undergoing aortic and mitral VinV implantation ( Figure 1B) . The median survival rates were 4.5 Ye et al. Tables 1 and 3 .
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Ye et al. Stroke following aortic TAVI is one of the major concerns in patients with native aortic stenosis.
Degenerated bioprosthetic valve leaflets are generally more friable than stenotic native valve leaflets and prone to tearing, which theoretically leads to a higher risk of acute neurological events. However, the incidence of stroke in patients with VinV implantation is equivalent to those in patients with TAVI for native aortic stenosis. Our stroke rate was 1.4% following Figure 2 .
VinV, which is similar to the global registry data (2%).
Heart block or aortic rupture was an extremely rare complication because the transcatheter valve is If necessary to achieve these goals, enlargement of the aortic annulus and/or aortic root (sinus Valsalva) may be considered to allow future VinV therapy with satisfactory outcomes. As an alternative, a more durable mechanical valve might be considered.
POST-OPERATIVE ANTICOAGULATION. It has been our practice to recommend aspirin indefinitely and clopidogrel for at least 3 months to patients following native aortic valve TAVI. In aortic VinV patients, we continue using the same protocol that is used in patients with TAVI. However, the observation of mitral valve thrombus in 2 patients has led to our current practice of aspirin indefinitely with the addition of warfarin for at least 3 months following mitral VinV implantation in patients without atrial fibrillation. An embolic complication from either aortic or mitral valve thrombosis appears rare, as we did not observe this in our patients who were diagnosed with valve thrombosis. Clearly, optimal anticoagulation following VinV therapy requires further study.
CONCLUSIONS
Transcatheter VinV implantation with balloonexpandable valves for failed aortic or mitral surgical bioprostheses can be performed safely with a high success rate and minimal early mortality and morbidity. Transcatheter VinV implantation provides encouraging mid-term clinical and hemodynamic outcomes in this high-risk elderly cohort of patients.
The appeal of this less-invasive approach to bioprosthetic valve failure may be compelling in patients for whom repeat surgery would be high risk. In patients undergoing conventional surgery with a bioprosthesis, efforts should be made to implant a bioprostheses large enough to allow for a future VinV implant with optimal hemodynamics and clinical outcomes. Mid-Term Outcome of Valve-In-Valve Implantation
